ehaweb.org
Panel Discussion
EHA Library, G Tonon, 337379
The Relevance of TCR Sequencing-Based Determination of the Cellular Immune Response in SARS-CoV-2 Infection
EHA Library, G Tonon, 337378
Monitoring Measurable Residual Disease (MRD) for Clinical Decision-Making in Acute Lymphoblastic Leukemia (ALL)
EHA Library, L Muffly, 337377
Q&A
EHA Library, B Inusa, 337372
Q&A
EHA Library, B Inusa, 337369
Undetectable Peripheral Blood Measurable Residual Disease (MRD), and relevance of ctDNA, for the Management of Chronic Lymphocytic Leukemia (CLL) Patients.
EHA Library, P Blombery, 337366
Assessment of Undetectable Minimal Residual Disease (MRD) and Time-Limited therapy in Chronic Lymphocytic Leukemia (CLL) Routine Clinical Practice.
EHA Library, J Pagel, 337364
Very low incidence of thrombosis in patients with ITP treated with fostamatinib; a pointer towards a novel antithrombotic pathway
EHA Library, P Nicolson, 337363
Panel discussion / Q&A
EHA Library, N Cooper, 337362
Targeted immune stimulation in myeloma: Immuno- and cellular therapies
EHA Library, N Raje, 337300
Story of hope – Key decisions in relapse treatment
EHA Library, MA Dimopoulos, 337303
Set new goals – New momentum in first-line therapy
EHA Library, O Landgren, 337305
A bright future - Evaluation of emerging therapies
EHA Library, G Cook, 337306
THE EVOLVING TREATMENT PARADIGM IN MYELOFIBROSIS
EHA Library, J Garcia, 337307
Q&A and discussion
EHA Library, K Linton, 337310
Closing remarks
EHA Library, K Linton, 337311
Integrating cell therapies in the treatment of DLBCL
EHA Library, P Barba, 337312
CAR T cell therapy in CLL: latest achievements and perspectives
EHA Library, A Kittai, 337314
The Role of Emerging Treatments and Management Approaches in Cold Agglutinin Disease
EHA Library, A Röth, 337316
Pathophysiology of Cold Agglutinin Disease – Understanding the Complement System
EHA Library, S Berentsen, 337320
Panel discussion: Beyond chemotherapy: advancing the treatment of ALL with immuno-oncology therapy
EHA Library, R Foà, 337322
Treatment of first relapse in childhood BCP-ALL
EHA Library, F Locatelli, 337324
Consolidation therapy for adult ALL: targeting minimal residual disease
EHA Library, N Gökbuget, 337325
Evolving approaches to treating early ITP
EHA Library, V McDonald, 337326
AML treatment choices: key data and perspectives
EHA Library, MT Voso, 337328
Introduction to MF treatment and management
EHA Library, F Cervantes, 337330
The evolution of MF treatment - how I manage MF today
EHA Library, J Mascarenhas, 337331
Preparing for the future of MF management
EHA Library, A Reiter, 337332
How I manage AML in the era of novel treatments, plus panel discussion
EHA Library, E Stein, 337333
Interactive panel discussion and Q&A
EHA Library, A Davies, 337334
Introduction
EHA Library, M Machaczka, 337339
Case 2: For Sherlock Holmes it’s never too late
EHA Library, A Pession, 337344
Post-session Survey
EHA Library, G Jackson, 337348
Case-Based Discussion: Treatment Across the Spectrum of Relapsed/Refractory Disease
EHA Library, G Jackson, 337349
The Monoclonal Antibody Landscape in Relapsed/Refractory Multiple Myeloma
EHA Library, E Ocio, 337350
Panel Discussion and Audience Q & A
EHA Library, C Buske, 337354
Rationale for Targeting TLR/BCR in Indolent Lymphomas – Role of BTK inhibition as Treatment Option for WM and MZL
EHA Library, S Treon, 337356
MZL – SoC and Role of BTK inhibitors now and in future
EHA Library, A Tedeschi, 337357
WM and MZL – disease, diagnosis, role of TLR/BCR pathway
EHA Library, S D’Sa, 337358
Evidence from clinical trials for the role of fostamatinib in ITP
EHA Library, W Ghanima, 337359
Welcome & Introduction
EHA Library, N Cooper, 337361
Panel Discussion
EHA Library, J Pagel, 337365
Serial Monitoring of Measurable Residual Disease (MRD) by NGS in the Context of Effective Chronic Lymphocytic Leukemia (CLL) Therapy.
EHA Library, O Al-Sawaf, 337367
Q&A and closing remarks
EHA Library, B Inusa, 337368
Introduction
EHA Library, B Inusa, 337370
Fundamentals of sickle cell disease: Understanding the pathophysiology and course of the disease
EHA Library, B Inusa, 337371
Evidence-based mini-review: The role of hemolysis and anemia in the progression of SCD
EHA Library, E Vichinsky, 337373
Managing patients with hemolytic anemia and comorbidities: Patient cases
EHA Library, C Minniti, 337374
Assessment of Measurable Residual Disease (MRD) Status for the Management of Patients with Acute Lymphoblastic Leukemia (ALL).
EHA Library, E Jabbour, 337376
Other applications of Syk inhibition: its role in wAIHA and Covid.
EHA Library, Q Hill, 337360
WM – SoC and Role of BTK inhibitors now and in future
EHA Library, C Buske, 337355
Welcome & Introductions
EHA Library, C Buske, 337353
IMCD IS NOT AN INDOLENT DISEASE: REAL-WORLD EVIDENCE SUGGESTS WE MUST ACT IMMEDIATELY
EHA Library, M Streetly, 337352
Monoclonal Antibodies in Multiple Myeloma: New Trials and Combinations
EHA Library, F Schjesvold, 337346
Case 5: Holmes and Watson’s involvement is only skin-deep
EHA Library, A Pession, 337345
Audience Q & A
EHA Library, C Bygrave, 337351
Welcome and Introductions
EHA Library, G Jackson, 337347
Case 1: A case of double trouble
EHA Library, H Rosenbaum, 337343
Case 4: Solving the case of the White Storm
EHA Library, H Rosenbaum, 337342
The importance of immune microenvironment in multiple myeloma and current treatment landscape
EHA Library, P Rodriguez Otero, 337298
Broad immune stimulation in myeloma: The role of cereblon modulators
EHA Library, P Richardson, 337299
THE CHANGING FACE OF AML INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
EHA Library, G Roboz, 337301
Introduction
EHA Library, MA Dimopoulos, 337302
Panel discussion & concluding remarks
EHA Library, MA Dimopoulos, 337304
Welcome and introduction
EHA Library, K Linton, 337308
Indolent NHL: current practices and new treatment paradigm
EHA Library, K Linton, 337309
Immuno-oncology agents in the treatment landscape of cHL
EHA Library, M André, 337313
Welcome, Introductions Pre-Test
EHA Library, A Röth, 337315
Post-test and Q&A
EHA Library, A Röth, 337317
Methods to Facilitate Early and Accurate Diagnosis in Cold Agglutinin Disease
EHA Library, W Barcellini, 337318
The Burden of Cold Agglutinin Disease
EHA Library, C Broome, 337319
Frontline therapy of adult Ph-positive ALL
EHA Library, R Foà, 337321
Welcome and introduction
EHA Library, R Foà, 337323
Putting theory into practice: case-based discussions around early ITP
EHA Library, V McDonald, 337327
Panel discussion and closing remarks
EHA Library, F Cervantes, 337329
Where are we now with the management of follicular lymphoma?
EHA Library, A Davies, 337335
New challenges in the evolving follicular lymphoma treatment landscape
EHA Library, K Hübel, 337336
Case discussion: What can we do to optimise initial therapy in follicular lymphoma?
EHA Library, M Caballero, 337337
Case discussion: How can we improve the management of relapsed/refractory follicular lymphoma?
EHA Library, T Vassilakopoulos, 337338
Live Q&A and conclusions
EHA Library, M Machaczka, 337340
Case 3: It’s simple Watson – persistence pays off!
EHA Library, M Machaczka, 337341
Patient care - part 1
EHA Library, Eoin McGrath, 313555
Abstract Book 2020
EHA Library, Faculty / Presenters, 307451
Educational Updates in Hematology 2020
EHA Library, Faculty / Presenters, 307450
Metabolomics - Can we cure cancer by metabolic conditioning?
EHA Library, Vassiliki Boussiotis, 313420
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VENETOCLAX WITH AZACITIDINE VS AZACITIDINE IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE THERAPY-VIALE-A
EHA Library, Courtney DiNardo, 303390
REAL-TIME NATIONAL SURVEY OF COVID-19 IN HEMOGLOBINOPATHY AND RARE INHERITED ANEMIA PATIENTS
EHA Library, Paul Telfer, 303394
ENDOTHELIOPATHY IS ESSENTIAL IN COVID-19 ASSOCIATED COAGULOPATHY
EHA Library, George Goshua, 303393
PHASE II RANDOMIZED CLINICAL TRIAL COMPARING ROPEGINTERFERON VERSUS PHLEBOTOMY IN LOW-RISK PATIENTS WITH POLYCYTHEMIA VERA. RESULTS OF THE PRE-PLANNED INTERIM ANALYSIS
EHA Library, Tiziano Barbui, 303391
SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: PRIMARY RESULTS FROM THE PHASE 3 ANDROMEDA STUDY
EHA Library, Efstathios Kastritis, 303396
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
EHA Library, Philippe Moreau, 303392
What I need to know about advanced therapy medicinal products for my clinical practice – facts or fiction: An interactive d
EHA Library, Joseph Mikhael, 312346
Future horizons for CAR T-cells, bispecifics and other advanced therapy medicinal products in multiple myeloma
EHA Library, Hermann Einsele, 312348
How molecular insights are changing the way we understand individual patients
EHA Library, Stefano Pileri, 312354
Interactive session: Welcome and voting on patient cases
EHA Library, Georg Heß, 312353
Can novel approaches for early response assessment guide timely clinical decisions?
EHA Library, A Schuh, 312352
Part II: Case studies, panel discussion and Q&A - From science to practice – a step closer to personalised care in NHL? - F
EHA Library, Faculty / Presenters, 312351
Are we ready to treat high-risk patients with DLBCL differently? Personalising front-line therapy – when standard treatment
EHA Library, Ulrich Jäger, 312350
Session Opening & Current landscape in the management of multiple myeloma
EHA Library, Mohamad Mohty, 312349
Panel Discussion and Q&A
EHA Library, Faculty / Presenters, 312347

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings